These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17170523)

  • 21. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
    Bock HA; Hirt-Minkowski P; Brünisholz M; Keusch G; Rey S; von Albertini B;
    Nephrol Dial Transplant; 2008 Jan; 23(1):301-8. PubMed ID: 17890745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
    Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.
    Allon M; Kleinman K; Walczyk M; Kaupke C; Messer-Mann L; Olson K; Heatherington AC; Maroni BJ
    Clin Pharmacol Ther; 2002 Nov; 72(5):546-55. PubMed ID: 12426518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
    Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose conversion ratio one year after switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients.
    Hirai T; Nakashima A; Shiraki N; Takasugi N; Yorioka N
    Int J Artif Organs; 2010 May; 33(5):283-9. PubMed ID: 20593349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Darbepoetin in the treatment of the renal anaemia in the patient undergoing peritoneal dialysis previously treated with epoetin alfa].
    Remón C; Quirós P; Fernández Marchena D; Hernández Romero M; del Castillo R; Fernández Ruiz E
    Nefrologia; 2005; 25(2):170-7. PubMed ID: 15912654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.
    Vekeman F; McKenzie RS; Lefebvre P; Watson SH; Mody SH; Piech CT; Duh MS
    Am J Health Syst Pharm; 2007 Sep; 64(18):1943-9. PubMed ID: 17823106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
    Thames WA; Smith SL; Scheifele AC; Yao B; Giffin SA; Alley JL
    Pharmacotherapy; 2004 Mar; 24(3):313-23. PubMed ID: 15040644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.
    Brophy DF; Ripley EB; Kockler DR; Lee S; Proeschel LA
    Ann Pharmacother; 2005 Nov; 39(11):1808-11. PubMed ID: 16189281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.
    Barnett AL; Crémieux PY
    Pharmacotherapy; 2003 May; 23(5):690-3; discussion 693-4. PubMed ID: 12741447
    [No Abstract]   [Full Text] [Related]  

  • 39. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD; Davidson SL; Tomita DK; Green L; Smith RE; Boccia RV
    Am J Health Syst Pharm; 2005 Jan; 62(1):54-62. PubMed ID: 15658073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.